Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Amgen expected to enter a guilty plea to unspecified charges

Amgen expected to enter a guilty plea to unspecified charges

Two cups of milk per day is enough to maintain adequate vitamin D levels for children

Two cups of milk per day is enough to maintain adequate vitamin D levels for children

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

High-risk leukemia patients respond to novel drug

High-risk leukemia patients respond to novel drug

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

Recurrence unlikely in childhood cryptogenic stroke

Recurrence unlikely in childhood cryptogenic stroke

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Pomalidomide safe and effective in treating multiple myeloma

Pomalidomide safe and effective in treating multiple myeloma

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Beth Israel Deaconess Medical Center introduces CeliacNow website

Beth Israel Deaconess Medical Center introduces CeliacNow website

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

New technology allows noninvasive SpHb assessments for children undergoing brain surgery

New technology allows noninvasive SpHb assessments for children undergoing brain surgery

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.